The Gulf countries have been working on the unified tourist visa – similar to Schengen-style visa – for over one year
Gulf Pharmaceutical Industries, popularly known as Julphar, on Sunday said it generated Dh221.3 million in sales during the second quarter of 2021, reflecting an increase of 30 per cent from the same quarter last year.
Julphar, one of the largest pharmaceutical manufacturers in the Middle East and Africa, said it has returned to profitability in April-June 2021 quarter for the first time in three years. The positive trajectory has been fuelled by the revenue growth of high margin products and the manufacturing of the Covid-19 vaccine Hayat-Vax, combined with the positive effects of implemented cost saving measures.
The successful re-entry into core markets such as Saudi Arabia, Oman, Bahrain and Kuwait continued in the past quarter. Progress in the divestment of non-core activities as well as a one-time gain from the settlement of past outstanding balances with distributors have also contributed to the company’s return to profitability.
Additionally, the company considerably strengthened its balance sheet position and reduced its liabilities by Dh309 million, driven by the settlement of previous customer obligations, the restructuring of the bank loans and the divestment of non-core activities. The net profit from continuing operations for the period is Dh67.3 million with a positive EBITDA of Dh88.9 million.
“I am pleased to say that we have done exceptionally well during the first half of the year. The recovery of Julphar has been consistent and steady, and it is encouraging to witness the return to profitability which is testament to the management’s unwavering focus on not only recovering our leadership position, but also unlocking new opportunities for growth,” Saqer Humaid Al Qasimi, chairman of the board, Julphar, said.
Dr Essam Mohamed, chief executive officer of Julphar, said: “Our financial performance this quarter confirms the progress of Julphar’s financial turnaround, which we have been working towards as part of our vision to be a leader in pharmaceuticals serving those in need in the Mena region and beyond. In addition to the re-establishment of Julphar in our key markets, we are very proud of our role in manufacturing the Sinopharm Covid-19 vaccine Hayat-Vax, which marks a significant contribution to the health and well-being of people and, on a larger scale, the sustained economic recovery.”
Looking ahead, Julphar remains focused on expanding the sales activities in key markets to increase market share with its existing portfolio. Furthermore, the company will increase its efforts towards filling its product pipeline to accelerate the introduction of its new products (speciality differentiated generics) from its newly fuelled pipeline, which will make a transformational change to the company’s product portfolio.
— business@khaleejtimes.com
The Gulf countries have been working on the unified tourist visa – similar to Schengen-style visa – for over one year
Renowned French pastry chef Angelo Musa, who recently introduced two dining concepts in Dubai, shares tips on how to excel in pastry art
Sheeraz was generous in giving realistic and practical insights on how fame can completely change the trajectory of one’s career and brand
The Dh100-billion plan introduced by the city's Crown Prince aims at increasing economic productivity
It joins other Apple products that were already in the DMA net since September: iOS for iPhones, the App Store, and the Safari browser
Al Mansoori played an important role in the development of the economic relations in non-oil sector between Japan and the UAE
Mental health continues to be under-resourced in affluent nations with advanced healthcare systems
The work undertaken covered several types of sidewalks for pedestrians, crosswalks, service roads, and combined use